Altria Group (NYSE:MO)‘s stock had its “hold” rating reissued by research analysts at UBS AG in a research report issued on Tuesday.

The analysts wrote, “modest potential negatives.”In fact, the FDA’s new policy on tobacco is the “bigger overhang” as it could evolve into incremental federal cigarette regulation — an event that was previously viewed as being unlikely, the analyst continued. As a result, Altria’s longer-term growth assumptions are being called into question and a re-rating of the stock’s multiple is justified, as has been the case in prior periods of regulatory scrutiny.However, the FDA’s new policy shift will be slow to implement and represents no near-term impacts to Altria’s earnings per share, Powers added. Also, conversations with industry experts suggest that it will take several years before any tangible regulatory change on the industry takes hold.Related Links:Tobacco Reemerges As Hollywood Star, But Does The Screen Time Help?This Biometric ID System Allows You To Buy Weed, Booze And Other Controlled Products From A Vending Machine Posted-In: cigarettesAnalyst Color Price Target FDA Legal Top Stories Analyst Ratings Trading Ideas Best of Benzinga © 2017 Benzinga does not provide investment advice. All rights reserved.   Related Articles (MO) Reality Reflects Art: World Puts Grisly Graphics On Cigarette Packs; US Tries Different Approach Jim Cramer Shares His Thoughts On Sony, Microsoft, Valeant And Altria 5 Biggest Price Target Changes For Monday Benzinga's Top Upgrades, Downgrades For July 31, 2017 Mid-Afternoon Market Update: CyberOptics Drops After Q2 Results; Aaron's Shares Surge FDA's Nicotine Cut: Not As Bad As It Looks? View Comments and Join the Discussion! View the discussion thread. document.write(”) Newsletter & Alerts

Become a Wall-Street Wizard. Market in 5 Minutes Everything you need to know about the market – quick & easy. Daily Analyst Rating A summary of each day’s top rating changes from sell-side analysts on the street. FinTech Focus Yesterday’s biggest gainers and losers. As well as 10 stocks to keep an eye on for Today TERMS & CONDITIONS Thank You for registering for Benzinga’s newsletters and alerts. • The Daily Analysts Ratings email will be received daily between 7am and 10am. • The Market in 5 Minutes email will be received daily between 7am and 8am. • The Fintech Focus email will be received every Friday between 2pm and 5pm. If you have any questions as it relates to either of the three newsletters, please feel free to contact us at 1-877-440-ZING. Trending Recent 1 TEVA, XXII: 25 Stocks Moving In Monday's Pre-Market Session 2 TEVA: A Long Road To Recovery For Teva Pharmaceuticals; Morgan Stanley D… 3 AMZN: Fun Fact: Amazon's AWS Contributes More Than 100% Of Its… 4 FDC, TSN: 7 Stocks To Watch For August 7, 2017 5 GWPH, ZYNE: What Zynerba's Flop Means For CBD Thera… 6 CAR, GEO: Earnings Scheduled For August 7, 2017 7 ZYNE: Zynerba's Clinical-Trial Mi… 1 NVDA, AA: These Were The Most Bought And Sold Stocks In July 2 TWLO: Twilio Skyrockets After Earnings Beat, Raised Guidance 3 NFLX, FOXA: Comic Book Writer Mark Millar: 4 Things You May Not Know A… 4 PLC, MANU: Manchester United Surges On Report Of 'Mammo… 5 F, TSLA: The Path Toward Autonomy: Munster On Tesla… 6 AMTD, T: TD Ameritrade Investor Movement Ind… 7 WFM, AMZN: The Unstoppable Amazon; Ro… View upcoming Earnings, Ratings, Dividend and Economic Calendars. Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content. Popular ChannelsAnalyst RatingsBe Your Own BossETFsEconomicsForexHotNewsOptionsPress ReleasesStart-upsTechTools & FeaturesAffiliate ProgramPreMarket PrepFeedsNews WidgetReal Time FeedSitemapSubmit News TipsAbout BenzingaAbout UsLicensing and APIsApps (iOS and Android)Fintech AwardsBlogSyndicationIn the NewsCareersService StatusContact UsDisclaimerPrivacy PolicyTerms and Conditions Benzinga Partners 1 (877) 440-9464 (ZING) © Copyright Benzinga Benzinga – Feed Your Mind try pro News Markets Ratings Ideas Tech Small-Cap Personal Finance Premium Products Despite Risks, Covanta's Path To Improvement Has Become Clear Dynavax Up 70% After FDA Vote For Hepatitis B Vaccine

Analyst Recommendations for Altria Group (NYSE:MO)

Receive News & Ratings for Altria Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altria Group and related companies with's FREE daily email newsletter.